SEC Filings

8-K
MEDTRONIC PLC filed this Form 8-K on 11/21/2017
Entire Document
 


MEDTRONIC PLC
WORLD WIDE REVENUE
(Unaudited)
 
 
 
 
 
 
 
ADJUSTED
 
 
 
 
 
 
 
 
ADJUSTED
 
REPORTED
 
CONSTANT CURRENCY(2)
 
REVISED(3)
 
 
 
 
REPORTED
 
CONSTANT CURRENCY(2)
 
REVISED(3)
 
 
(in millions)
FY18
Q2
 
FY17
Q2
 
Reported
Growth
 
Currency Impact
 
FY18
Q2
 
FY17
Q2
 
Comparable Constant Currency Growth
 
 
FY18
Q2 YTD
 
FY17
Q2 YTD
 
Reported
Growth
 
Currency Impact
 
FY18
Q2 YTD
 
FY17
Q2 YTD
 
Constant Currency Growth
Cardiac & Vascular Group
$
2,773

 
$
2,584

 
7
 %
 
$
16

 
$
2,757

 
$
2,584

 
7
 %
 
 
$
5,419

 
$
5,102

 
6
 %
 
$
4

 
$
5,415

 
$
5,102

 
6
 %
Cardiac Rhythm & Heart Failure
1,467

 
1,400

 
5

 
6

 
1,461

 
1,400

 
4

 
 
2,857

 
2,734

 
4

 
(1
)
 
2,858

 
2,734

 
5

Coronary & Structural Heart
854

 
753

 
13

 
8

 
846

 
753

 
12

 
 
1,671

 
1,515

 
10

 
5

 
1,666

 
1,515

 
10

Aortic & Peripheral Vascular
452

 
431

 
5

 
2

 
450

 
431

 
4

 
 
891

 
853

 
4

 

 
891

 
853

 
4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Minimally Invasive Therapies Group(1)
1,952

 
2,473

 
(21)
 
8

 
1,944

 
1,910

 
2

 
 
4,438

 
4,897

 
(9)
 
(6
)
 
4,444

 
4,334

 
3

Surgical Innovations
1,334

 
1,271

 
5
 
8

 
1,326

 
1,271

 
4

 
 
2,733

 
2,619

 
4
 
(1
)
 
2,734

 
2,619

 
4

Respiratory, Gastrointestinal, & Renal
618

 
1,202

 
(49)
 

 
618

 
639

 
(3
)
 
 
1,705

 
2,278

 
(25)
 
(5
)
 
1,710

 
1,715

 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Restorative Therapies Group
1,863

 
1,826

 
2

 
4

 
1,859

 
1,826

 
2

 
 
3,672

 
3,598

 
2

 
(3
)
 
3,675

 
3,598

 
2

Spine
659

 
663

 
(1
)
 

 
659

 
663

 
(1
)
 
 
1,308

 
1,308

 

 
(3
)
 
1,311

 
1,308

 

Brain Therapies
575

 
506

 
14

 
2

 
573

 
506

 
13

 
 
1,097

 
995

 
10

 

 
1,097

 
995

 
10

Specialty Therapies
365

 
369

 
(1
)
 
1

 
364

 
369

 
(1
)
 
 
734

 
725

 
1

 

 
734

 
725

 
1

Pain Therapies
264

 
288

 
(8
)
 
1

 
263

 
288

 
(9
)
 
 
533

 
570

 
(6
)
 

 
533

 
570

 
(6
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diabetes Group
462

 
462

 

 
7

 
455

 
462

 
(2
)
 
 
911

 
914

 

 
7

 
904

 
914

 
(1
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TOTAL
$
7,050

 
$
7,345

 
(4
)%
 
$
35

 
$
7,015

 
$
6,782

 
3
 %
 
 
$
14,440

 
$
14,511

 
 %
 
$
2

 
$
14,438

 
$
13,948

 
4
 %
See description of non-GAAP financial measures at the end of the earnings press release.

(1) In the second quarter of fiscal year 2018, the Company realigned its divisions within the Minimally Invasive Therapies Group, which included a movement of revenue from certain product lines within Surgical Innovations to Respiratory Gastrointestinal & Renal. As a result, second quarter fiscal year 2017 results have been recast to adjust for this realignment. Results for the first quarter of fiscal year 2017 and 2018 included within the year-to-date figures herein have not been recast to adjust for this realignment.
(2) Constant currency adjusted revenue, a non-GAAP financial measure, presents current period revenue using average exchange rates in effect during the applicable prior year period.
(3) Revised revenue excludes revenue related to the divested Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for the second quarter of fiscal year 2017.

6

X